Do I need a prescription for Propafenone 150mg/5ml oral suspension?

Propafenone 150mg/5ml oral suspension is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Propafenone 150mg/5ml oral suspension?

Propafenone 150mg/5ml oral suspension is the generic name. It is available under brand names including: Propafenone 150mg/5ml oral suspension. (Source: NHS dm+d — Actual Medicinal Products)

Propafenone 150mg/5ml oral suspension

Prescription only

Requires a prescription from a doctor or prescriber

Oral suspension

150mg/5ml

Oral

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias.

Active ingredients:

Propafenone

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C01BC03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Propafenone

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Propafenone

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Propafenone

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Propafenone

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Propafenone on the MHRA register

Propafenone 150mg/5ml oral suspension

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Daily dose

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

Oral solution

25mg/5ml

Same therapeutic group

Propafenone 150mg/5ml oral solution

Oral solution

150mg/5ml

Same therapeutic group

Propafenone 50mg/5ml oral suspension

Oral suspension

50mg/5ml

Same therapeutic group

Propafenone 50mg/5ml oral solution

Oral solution

50mg/5ml

Same therapeutic group

Flecainide 200mg/5ml oral suspension

Oral suspension

200mg/5ml

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Guidelines from the National Institute for Health and Care Excellence

NICE clinical guidance(2)

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Atrial fibrillation: diagnosis and management (NG196)

NG196

NICE guideline

Updated Jun 2021

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

13149611000001109

dm+d ID

13149611000001109

VTM (Virtual Therapeutic Moiety)

777335006

VMP (Virtual Medicinal Product)

13149611000001109

BNF code (NHS dm+d)

02030200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C01BC03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 11 · Randomised trials: 4 · 1983–2024

Sort

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

Nick Freemantle, Carmelo Lafuente‐Lafuente, S. L. Mitchell, et al.

EP Europace, 2011

Meta-analysis

Highly cited for its field

Cited by 243

Dronedarone
Amiodarone
Anti-Arrhythmia Agents

Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation

Ijaz A. Khan

Journal of the American College of Cardiology, 2001

Meta-analysis

Cited by 142

Atrial Fibrillation
Clinical Trials as Topic
Electrocardiography

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis

Q. Tran, I. Baek, Nayoung Han, et al.

Pharmaceutics, 2022

Systematic review

Cited by 11

Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial

M. Balík, M. Maly, T. Brožek, et al.

Intensive Care Medicine, 2023

Randomised trial

Cited by 22

Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis

Sharon C. Reimold, William H. Maisel, Elliott M. Antman

The American Journal of Cardiology, 1998

Meta-analysis

Cited by 52

Anti-Arrhythmia Agents
Atrial Fibrillation
Propafenone

The Efficacy Comparison Between Guan-Fu Base A Hydrochloric Injection vs. Propafenone Hydrochloric Injection in the Treatment of Arrhythmia: Systemic Review and Meta-Analysis

Jinming Song, Yao Tang, Chao Gao, et al.

Frontiers in Cardiovascular Medicine, 2021

Meta-analysis

Cited by 4

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

L. Siddoway, K. Thompson, C. Mcallister, et al.

Circulation, 1987

Highly cited for its field

Cited by 291

Arrhythmias, Cardiac
Debrisoquin
Drug Evaluation

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

Sharon C. Reimold, Catherine Cantillon, Peter L. Friedman, et al.

The American Journal of Cardiology, 1993

Highly cited for its field

Cited by 255

Atrial Fibrillation
Propafenone
Recurrence

Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo‐controlled, double‐blind, multicenter clinical trial

Claudio Fresco, Alessandro Proclemer, Alessandro Pavan, et al.

Clinical Cardiology, 1996

Randomised trial

Cited by 65

Anti-Arrhythmia Agents
Atrial Fibrillation
Echocardiography

Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery

Stuart J. Connolly, Amin Mulji, Deborah L. Hoffert, et al.

Journal of the American College of Cardiology, 1987

Randomised trial

Cited by 58

Coronary Artery Bypass
Heart Rate
Heart Ventricles

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

2-10 hours

Mechanism

The electrophysiological effect of propafenone manifests itself in a reduction o…

Food interactions

2 warnings

Human targets

4 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

90%

Nearly completely absorbed following oral administration (90%).…

Half-life

2-10 hours

2-10 hours

Protein binding

97%

Volume of distribution

252 L

* 252 L

Metabolism

25%

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone.…

Elimination

50%

Approximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

Properties:

solid

Avg. mass: 341.44 Da

View FDA drug label

DrugBank indication

Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.

Also known as(64)

1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone

2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone

Propafenona

Propafenone

Propafenonum

hH1

Sodium channel protein cardiac muscle subunit alpha

Sodium channel protein type V subunit alpha

Molecular properties(19)

Drug interactions(1626)

Known interactions with other medications. Always consult a healthcare professional.

Afatinib

Unknown severity

DB08916

The serum concentration of Afatinib can be increased when it is combined with Propafenone.

Check this interaction

Bosutinib

Unknown severity

DB06616

The serum concentration of Bosutinib can be increased when it is combined with Propafenone.

Check this interaction

Brentuximab vedotin

Unknown severity

DB08870

The serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.

Check this interaction

Colchicine

Unknown severity

DB01394

The serum concentration of Colchicine can be increased when it is combined with Propafenone.

Check this interaction

Edoxaban

Unknown severity

DB09075

The serum concentration of Edoxaban can be increased when it is combined with Propafenone.

Check this interaction

Ledipasvir

Unknown severity

DB09027

The serum concentration of Ledipasvir can be increased when it is combined with Propafenone.

Check this interaction

Naloxegol

Unknown severity

DB09049

The serum concentration of Naloxegol can be increased when it is combined with Propafenone.

Check this interaction

Pazopanib

Unknown severity

DB06589

The serum concentration of Pazopanib can be increased when it is combined with Propafenone.

Check this interaction

Prucalopride

Unknown severity

DB06480

The serum concentration of Prucalopride can be increased when it is combined with Propafenone.

Check this interaction

Ranolazine

Unknown severity

DB00243

The serum concentration of Ranolazine can be increased when it is combined with Propafenone.

Check this interaction

Silodosin

Unknown severity

DB06207

The excretion of Silodosin can be decreased when combined with Propafenone.

Check this interaction

Topotecan

Unknown severity

DB01030

The serum concentration of Topotecan can be increased when it is combined with Propafenone.

Check this interaction

Ceritinib

Moderate

DB09063

Propafenone may increase the bradycardic activities of Ceritinib.

Check this interaction

Ivabradine

Moderate

DB09083

Propafenone may increase the bradycardic activities of Ivabradine.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Propafenone.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Propafenone can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Propafenone can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Propafenone can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.

Check this interaction

Remikiren

Moderate

DB00212

Propafenone may decrease the antihypertensive activities of Remikiren.

Check this interaction

Guanadrel

Moderate

DB00226

Propafenone may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Chlorthalidone

Moderate

DB00310

Propafenone may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Propafenone may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Propafenone may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Metolazone

Moderate

DB00524

Propafenone may decrease the antihypertensive activities of Metolazone.

Check this interaction

Cyclothiazide

Moderate

DB00606

Propafenone may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Propafenone may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Propafenone may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Nitroglycerin

Moderate

DB00727

Propafenone may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Metyrosine

Moderate

DB00765

Propafenone may decrease the antihypertensive activities of Metyrosine.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Propafenone may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Propafenone may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Fenoldopam

Moderate

DB00800

Propafenone may decrease the antihypertensive activities of Fenoldopam.

Check this interaction

Chlorothiazide

Moderate

DB00880

Propafenone may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Propafenone may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Pentolinium

Moderate

DB01090

Propafenone may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Propafenone may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

The metabolism of Propafenone can be decreased when combined with Diazoxide.

Check this interaction

Epoprostenol

Moderate

DB01240

Propafenone may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Polythiazide

Moderate

DB01324

Propafenone may decrease the antihypertensive activities of Polythiazide.

Check this interaction

Tienilic acid

Moderate

DB04831

Propafenone may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Propafenone may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Hexamethonium

Moderate

DB08960

Propafenone may decrease the antihypertensive activities of Hexamethonium.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Propafenone may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Angiotensin 1-7

Moderate

DB11720

Propafenone may decrease the antihypertensive activities of Angiotensin 1-7.

Check this interaction

BQ-123

Moderate

DB12054

Propafenone may decrease the antihypertensive activities of BQ-123.

Check this interaction

Guanoxan

Moderate

DB13211

Propafenone may decrease the antihypertensive activities of Guanoxan.

Check this interaction

Vincamine

Moderate

DB13374

Propafenone may decrease the antihypertensive activities of Vincamine.

Check this interaction

Linsidomine

Moderate

DB13400

Propafenone may decrease the antihypertensive activities of Linsidomine.

Check this interaction

Guanoxabenz

Moderate

DB13410

Propafenone may decrease the antihypertensive activities of Guanoxabenz.

Check this interaction

Showing 50 of 1626 interactions

Food & lifestyle interactions

Avoid Grapefruit

Avoid grapefruit products.

Advice

Take with or without food. Take consistently at the same time in regard to meals.

Toxicity & overdose

Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.

How it works

Mechanism of action

The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.

Pharmacodynamics

Propafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It acts by inhibiting sodium channels to restrict the entry of sodium into cardiac cells resulting in reduced excitation. Propafenone has local anesthetic activity approximately equal to procaine.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).

Half-life

2-10 hours

Protein binding

97%

Volume of distribution

* 252 L

Metabolism

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

Route of elimination

Approximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.

Drug targets(4)

Proteins and enzymes this drug interacts with in the body

Sodium channel protein type 5 subunit alpha

BE0000197

SCN5A

inhibitor

Specific functionankyrin binding

Cellular location

Cell membrane

General function & pharmacology

Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:1309946 PMID:21447824 PMID:23085483 PMID:23420830 PMID:25370050 PMID:26279430 PMID:26392562 PMID:26776555

Nav1.5 is the predominant sodium channel expressed in myocardial cells and it is responsible for the initial upstroke of the action potential in cardiac myocytes, thereby initiating the heartbeat .
PMID:11234013 PMID:11804990 PMID:12569159 PMID:1309946

Required for normal electrical conduction including formation of the infranodal ventricular conduction system and normal action potential configuration, as a result of its interaction with XIRP2 (By similarity)

Voltage-gated inwardly rectifying potassium channel KCNH2

BE0000090

KCNH2

inhibitor

Specific functiondelayed rectifier potassium channel activity

Cellular location

Cell membrane

General function & pharmacology

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245

Channel properties are modulated by cAMP and subunit assembly .
PMID:10837251
Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization .
PMID:10219239 PMID:10753933 PMID:10790218 PMID:10837251 PMID:11997281 PMID:12063277 PMID:18559421 PMID:22314138 PMID:22359612 PMID:26363003 PMID:27916661 PMID:9230439 PMID:9351446 PMID:9765245

Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity PMID:10219239 PMID:9230439

Beta-1 adrenergic receptor

BE0000172

ADRB1

antagonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.

Involved in the regulation of sleep/wake behaviors PMID:31473062

Beta-2 adrenergic receptor

BE0000694

ADRB2

antagonist

Specific functionadenylate cyclase binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

CYP3A4Cytochrome P450 3A4

substrate

CYP1A2Cytochrome P450 1A2

substrate

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

ATC classification(1 code)

ATC C01BC03

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Propafenone hydrochloride(DBSALT000148)

Experimental properties(2)

External resources(3)

RxList PDRhealth Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Propafenone

DB01182

CAS number

54063-53-5

UNII (FDA)

68IQX3T69U

InChI Key (molecular fingerprint)

JWHAUXFOSRPERK-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1893

ChEBI

63619

PubChem Compound

4932

PubChem Substance

46504529

KEGG Compound

C07381

KEGG Drug

D08435

ChemSpider

4763

BindingDB

50067133

PharmGKB

PA451131

Therapeutic Targets Database

DAP000497

IUPHAR

2561

Guide to Pharmacology

2561

Wikipedia

Propafenone

ChEMBL

CHEMBL631

RxCUI

8754

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10593

GenAtlas

SCN5A

GeneCards

SCN5A

GenBank Gene Database

M77235

GenBank Protein Database

184039

IUPHAR

582

Guide to Pharmacology

582

UniProtKB

Q14524

UniProt Accession

SCN5A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6251

GenAtlas

KCNH2

GeneCards

KCNH2

GenBank Gene Database

U04270

GenBank Protein Database

487738

IUPHAR

572

Guide to Pharmacology

572

UniProtKB

Q12809

UniProt Accession

KCNH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(4 Mar 2026)

Structured knowledge from the free knowledge base

Q662511

Wikipedia article

group of stereoisomers

Read on Wikipedia

WHO INN:propafenone

International Nonproprietary Name

Research database identifiers

MeSH

D011405

ChEBI

CHEBI:63619

ATC classifications (Wikidata)

C01BC03

Linked open data from Wikidata (Q662511), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.

Source: Q662511CC0 1.0

Updated about 9 hours ago(5 Jul 2026)

Back to medicines

Propafenone 150mg/5ml oral suspension

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

Propafenone

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Propafenone 150mg/5ml oral suspension

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

NICE clinical guidance

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

Propafenone

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
8